Navigation Links
Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
Date:6/3/2010

RICHMOND, Calif., June 3 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, and Ward Wolff, executive vice president and CFO, will provide an update on the progress of Sangamo's ZFP Therapeutic™ development programs and an overview of the company's business strategy at two investor conferences during the month of June:

  • The Jefferies 2010 Global Life Sciences Conference, at 9:00 am ET on Tuesday, June 8.
  • The 9th Annual Needham Healthcare Conference in New York City, at 10:40 am ET on Thursday, June 10.

Live webcasts of the presentations will be available on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. A replay of each presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic™ development program is currently in a Phase 2b clinical trial for evaluation of safety and clinical effect in patients with diabetic neuropathy and a Phase 2 trial in ALS. Sangamo also has two Phase 1 clinical trials to evaluate safety and clinical effect of a treatment for HIV/AIDS and another Phase 1 trial to evaluate safety and clinical effect of a treatment for recurrent glioblastoma multiforme. Other therapeutic development programs are focused on neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases.  Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFNs) for gene modification. Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at http://www.sangamo.com/.


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sangamo BioSciences and Collaborators Present Data in Fifteen Presentations Highlighting Broad Therapeutic Applications of ZFP Technology
2. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
3. Sangamo BioSciences Announces Presentation at Cowen and Company Health Care Conference
4. Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results
5. Sangamo BioSciences Announces Presentation at BIO CEO & Investor Conference
6. Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS
7. Sangamo BioSciences Announces Presentation at Merriman Curhan Fords Investor Summit 2009
8. Sangamo BioSciences Announces Third Quarter 2009 Conference Call and Webcast
9. Sangamo Announces Pricing of Public Offering of Common Stock
10. Sigma-Aldrich(R) and Sangamo BioSciences Announce Major Expansion of ZFP Technology License Agreement
11. Sangamo BioSciences Announces Presentation at the UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... 11, 2016 Non-profit Consortium Aims to ... to Support Research and Discovery --> ... an ambitious plan to sequence 100,000 individuals. It is intended ... at least 7 of North and East Asian countries. ... phase, the project will focus on creating phased reference genomes ...
(Date:2/11/2016)...  Vermillion, Inc. (NASDAQ: VRML ), a bio-analytical ... formation of the Steering Committee for its Pelvic Mass ... Pelvic masses can present physicians and healthcare professionals ... is ruled out, pelvic masses may include cancers of ... ovarian tumors and gastrointestinal and urinary tract masses. ...
(Date:2/11/2016)... -- Bioethics International, a not-for-profit organization focused on the ethics and ... accessible to patients around the world, today announced that the ... of the Good Pharma Scorecard an ,Editors, ... one of BMJ Open ,s ,Most Popular Articles, which ... frequently read. Ed Sucksmith , assistant editor of ...
(Date:2/11/2016)... , Feb. 11, 2016  Wellcentive today ... Portland, Oregon -based community care ... provide population health analytics, quality reporting and care ... FamilyCare strengthen its team of quality managers, analysts ... to the provider groups serving FamilyCare members. ...
Breaking Biology Technology:
(Date:2/2/2016)... , Feb. 2, 2016 Technology Enhancements Accelerate ... an analysis of the digital and computed radiography markets ... , and Indonesia (TIM). ... and market size, as well as regional market drivers ... and discusses market penetration and market attractiveness, both for ...
(Date:2/1/2016)... Fla. , Feb. 1, 2016  Wocket® smart wallet ( www.wocketwallet.com ... and television personality, Joey Fatone . Las Vegas ... greet fans. --> Las Vegas , where ... --> The new video ad was filmed at the Consumer ... appeared at the Wocket booth to meet and greet fans. ...
(Date:1/22/2016)... 2016 http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ... the  "Global Behavioral Biometric Market 2016-2020" ... http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced the ... Market 2016-2020"  report to their offering. ... http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced the addition ...
Breaking Biology News(10 mins):